WINDLAS · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 35/100 — Quality 53 · Valuation 19 · Momentum 20
| Share price | ₹871.55 |
| Market cap | ₹1,713 Cr |
| P/E ratio | 26.7 |
| P/B ratio | 3.3 |
| ROE | 19.6% |
| ROCE | 15.7% |
| Dividend yield | 0.76% |
| Book value | ₹254.44 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹904 Cr | ₹66 Cr | 12.0% |
| 2025 | ₹760 Cr | ₹61 Cr | 12.0% |
| 2024 | ₹631 Cr | ₹58 Cr | 12.0% |
| 2023 | ₹513 Cr | ₹43 Cr | 12.0% |
| 2022 | ₹466 Cr | ₹38 Cr | 11.0% |
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company o